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Abstract 
We discuss the case of synchronous bilateral lung cancers which feature the same histological 
phenotype and a different EGFR mutational profile. Both histological and molecular charac-
terizations were performed on specimens derived thorough CT-guided fine needle aspiration. 
A first-line chemotherapy was unsuccessful. Subsequent objective response to the EGFR in-
hibitor Erlotinib was clearly coherent with the sequencing data and the mutated nodule was 
effectively reduced (> 50%) after therapy, while the lesion assessed as EGFR wild type fea-
tured a slight response. This report has two relevant implications. It points out that in case of 
multiple malignant lesions at time of diagnosis, molecular profiling should be as extensive as 
possible and it might contribute to clarify the association between the lesions found. Besides 
the molecular analysis on cytology specimens could identify an accurate and safe diagnostic 
approach for clinical use. 
Key words: synchronous bilateral lung cancer 
Introduction 
Correlation between mutations in cancer alleles 
and drug response is a key point to identify drugs or 
drug combinations that match the genetic profile of 
individual  tumors.  The  identification of  genetic  de-
terminants  of  drug  response,  by routine  diagnostic 
approaches,  is  thus  a  clear  priority  of  translational 
oncology. In Non-Small Cell Lung Cancer (NSCLC) 
genetic lesions affecting the Epidermal Growth Factor 
Receptor (EGFR) pathway act as predictive markers 
of response to small inhibitors1. Inappropriate EGFR 
overactivation is mainly consequent to somatic mu-
tations occurring in those sequences which encode for 
the  receptor  tyrosine  kinase  (TK)  domain  2.  EGFR 
amplification  (detected  by  FISH  in  20-40%  of 
NSCLCs, according to different studies) seems to add 
a gain in response rates to Gefitinb and Erlotinib 3,4,5. 
On  the  other  hand,  mutations  affecting  the  EGFR 
downstream transducers  and  mainly  the  KRAS on-
cogene have emerged as highly specific negative pre-
dictors of response to single anti-EGFR agents 6. 
Case 
Here  we  describe  the  case  of  a  71  years  old, 
currently  smoker,  Caucasian  man  who  came  under 
our  observation  due  to  the  occasional  detection  by 
standard  chest  X  ray  of  a  right  pulmonary  mass. 
During hospitalization, the patient underwent a total 
body CT scan that showed the presence of two solid 
parenchymal  lesions:  the  first  affecting  the  upper 
right lobe and a second nodule at the lower left lobe; 
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no  mediastinal  and  extrathoracic  masses  were  de-
tected.  The  subsequently  performed  endoscopical 
examination did  not  allow conclusive findings. The 
patient was then addressed to fluoroscopic CT-guided 
fine  needle  aspiration  (FNA)  of  the  two  lesions.  In 
both cases the cytological analysis (Fig. 1) was con-
sistent with adenocarcinoma, displaying a TTF-1 and 
p63  positive  immunohistochemical  profile.  A  diag-
nosis  of  bilateral  synchronous  NSCLC  (adenocarci-
noma) was thus formulated. In order to evaluate the 
EGFR/KRAS mutational profile, tumor genomic DNA 
from formalin-fixed paraffin-embedded (FF-PE) cor-
responding  samples  was  extracted  and  sequenced. 
Interestingly  two  different  EGFR  profiles  were  un-
veiled. Indeed we found that the right lesion carried 
the  EGFR  L858R  somatic  change,  while  no  EGFR 
mutations  were  detected  by  sequencing  genomic 
DNA  extracted  from  the  left  nodule.  Absence  of 
EGFR  amplification  was  documented  by  FISH 
analysis  on  both  lesions.  Besides  the  two  masses 
harboured  wild type KRAS sequences. 
On this evidence, the patient underwent a first 
line  platinum-based  chemo  (platinum-pemetrexed) 
but  a  slight  disease  progression  was  documented 
subsequent to 4 cycles of treatment. For that reason 
the  patient  was  then  treated  with  Erlotinib  150 
mg/die. After 6 months of treatment the EGFR mu-
tated  lesion  displayed  a  volume  reduction  of  more 
than 50%; the controlateral nodule showed a less but 
still significant (15 %) reduction in both diameter and 
density (Fig.2). Overall CT scans were performed as a 
control  after  therapies  and  objective  response  was 
evaluated according to RECIST criteria7. 
 
Figure 1 Formalin-fixed paraffin-embedded (FF-PE) samples of CT-guided fine needle aspiration of both the right (A) and 
the left (B) nodule (Hematoxylin and eosin stain, 40X.)  
 
Figure 2. Evolution of tumor lesions after 6 months therapy with erlotinib as documented by CT scan. Panel A: thoracic CT 
scan, after chemotherapy. Panel B: thoracic CT scan after 6 months of therapy with erlotinib, 150 mg/die.  Journal of Cancer 2011, 2 
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Discussion 
The above discussed case seems worth to be re-
ported since it allows relevant some clinical consider-
ations. 
Interestingly,  the  lesion  that  was  assessed  as 
EGFR  wild  type  -  by  sequencing  FNA  cytology 
specimen- actually displayed a slight response to the 
EGFR inhibitor. This behavior could be coherent with 
the fact that some responses to EGFR TKIs have been 
described also in EGFR wild type tumors8. In addi-
tion,  it  could  be  hypothesized  the  presence  of  an 
EGFR-mutated  subclone.  From  this  perspective,  it 
should be note that direct sequencing might not be 
sensitive enough to detect low frequency of mutated 
EGFR and KRAS even though it remains at the pre-
sent  among  the  most  accurate approaches to  muta-
tional analysis for clinical running. 
A  second  key  point  is  represented  by  the  fact 
that routine histochemistry classified these tumors as 
two  independent  synchronous  lung  cancers.  How-
ever  based  on  their  mutational  profile,  a  potential 
chronology  and  a  metastatic  progression  could  be 
hypothesized.  Indeed  preclinical  data  suggest  that 
EGFR  mutations  occur  as  an  early  event  during 
NSCLC onset 9. Besides it is known that the molecular 
status of EGFR/KRAS may change during the distant 
spreading of NSCLC  12,10 and a discordance between 
EGFR mutations in primary tumors and their corre-
sponding lymphatic and distant metastases has been 
already reported 11,12,13,14. The heterogeneity found in 
this case has relevant clinical implications since it is 
reflected  in  disease  staging  and  therapy:  if  the  pu-
tative  second  lesion  was  a  metastasis,  that meant a 
stage IV - not resectable - disease, whereas if it was a 
synchronous  primary  tumor,  it  was  potentially  re-
sectable15.  Although  an  exhaustive  immunoisto-
chemical analysis could be helpful to clarify the asso-
ciation between the  two  lesions,  this  case  undoubt-
edly  demonstrates  that  regardless  histochemistry, 
therapy  should  be  tailored  to  the molecular profile 
and that a molecular profile can be linked to a clinical 
phenotype. 
A  third  issue  is  related  to  the  opportunity  to 
routinely perform EGFR/KRAS mutational profile in 
front of ADKs aroused in males and active smokers. 
From this perspective, this report provides clear evi-
dence for a need to a complete EGFR/KRAS molec-
ular profiling for all lung ADKs. 
Finally this clinical report underlines the role of 
molecular diagnosis on cytological tumor sample as a 
routinely  safe  and  accurate  approach.  Coherently 
recent  reports  confirm  the  feasibility  of  these  tech-
niques in samples derived from US-guided fine nee-
dle  biopsies  16,17.  However  it  should  be  noted  that 
although mutational analysis on small sized samples 
may  underestimate  molecular  heterogeneity  that 
usually  characterizes  lung  cancer  and  that,  conse-
quently, the fraction of the mutated EGFR might be 
kept in consideration to define to what extent a lesion 
is mutated and consequently objectively sensitive to 
anti EGFR therapy. 
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